BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 31452441)

  • 1. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.
    Bullock M; Lim G; Zhu Y; Åberg H; Kurdyukov S; Clifton-Bligh R
    Thyroid; 2019 Nov; 29(11):1623-1633. PubMed ID: 31452441
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
    McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
    Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
    Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
    Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
    Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
    Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
    Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
    PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.
    Stern JL; Hibshman G; Hu K; Ferrara SE; Costello JC; Kim W; Tamayo P; Cech TR; Huang FW
    Mol Cancer Res; 2020 Jul; 18(7):1050-1062. PubMed ID: 32276990
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Rusinek D; Pfeifer A; Cieslicka M; Kowalska M; Pawlaczek A; Krajewska J; Szpak-Ulczok S; Tyszkiewicz T; Halczok M; Czarniecka A; Zembala-Nozynska E; Chekan M; Lamch R; Handkiewicz-Junak D; Ledwon A; Paliczka-Cieslik E; Kropinska A; Jarzab B; Oczko-Wojciechowska M
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32560331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly recurrent TERT promoter mutations in human melanoma.
    Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
    Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
    Bell RJ; Rube HT; Kreig A; Mancini A; Fouse SD; Nagarajan RP; Choi S; Hong C; He D; Pekmezci M; Wiencke JK; Wrensch MR; Chang SM; Walsh KM; Myong S; Song JS; Costello JF
    Science; 2015 May; 348(6238):1036-9. PubMed ID: 25977370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects.
    Landa I; Thornton CEM; Xu B; Haase J; Krishnamoorthy GP; Hao J; Knauf JA; Herbert ZT; Martínez P; Blasco MA; Ghossein R; Fagin JA
    Mol Cancer Res; 2023 Nov; 21(11):1163-1175. PubMed ID: 37478162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase (
    Yoo H; Kim HS
    Cancer Genomics Proteomics; 2023; 20(6):626-636. PubMed ID: 37889060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter alterations could provide a solution for Peto's paradox in rodents.
    Vedelek B; Maddali AK; Davenova N; Vedelek V; Boros IM
    Sci Rep; 2020 Nov; 10(1):20815. PubMed ID: 33257697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
    Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
    Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.
    Tsai JW; Cejas P; Wang DK; Patel S; Wu DW; Arounleut P; Wei X; Zhou N; Syamala S; Dubois FPB; Crane A; Pelton K; Vogelzang J; Sousa C; Baguette A; Chen X; Condurat AL; Dixon-Clarke SE; Zhou KN; Lu SD; Gonzalez EM; Chacon MS; Digiacomo JJ; Kumbhani R; Novikov D; Hunter J; Tsoli M; Ziegler DS; Dirksen U; Jager N; Balasubramanian GP; Kramm CM; Nathrath M; Bielack S; Baker SJ; Zhang J; McFarland JM; Getz G; Aguet F; Jabado N; Witt O; Pfister SM; Ligon KL; Hovestadt V; Kleinman CL; Long H; Jones DTW; Bandopadhayay P; Phoenix TN
    Cancer Res; 2022 Sep; 82(17):2980-3001. PubMed ID: 35802025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma.
    Póvoa AA; Teixeira E; Bella-Cueto MR; Batista R; Pestana A; Melo M; Alves T; Pinto M; Sobrinho-Simões M; Maciel J; Soares P
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled genetic screens to identify vulnerabilities in TERT-promoter-mutant glioblastoma.
    Tu KJ; Stewart CE; Hendrickson PG; Regal JA; Kim SY; Ashley DM; Waitkus MS; Reitman ZJ
    Oncogene; 2023 Oct; 42(44):3274-3286. PubMed ID: 37741952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERTmonitor-qPCR Detection of
    Brás JP; Jesus TT; Prazeres H; Lima J; Soares P; Vinagre J
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E4F1 and ZNF148 are transcriptional activators of the -57A > C and wild-type
    Chua BH; Zaal Anuar N; Ferry L; Domrane C; Wittek A; Mukundan VT; Jha S; Butter F; Tenen DG; Defossez PA; Kappei D
    Genome Res; 2023 Nov; 33(11):1893-905. PubMed ID: 37918959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipocyte signaling affects thyroid-specific gene expression via down-regulation of TTF-2/FOXE1.
    Zamboni M; Strimpakos G; Poggiogalle E; Donini LM; Civitareale D
    J Mol Endocrinol; 2023 Jan; 70(1):. PubMed ID: 36347053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.
    Sang Y; Hu G; Xue J; Chen M; Hong S; Liu R
    Endocrine; 2024 Feb; ():. PubMed ID: 38356100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.